Company Overview
Company Type: Public Company
Website: marvelbiotechnology.com
Number of Employees: -
Ticker: MRVL (TSXV)
Year Founded: -


Business Description
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer’s disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
2.8
EBITDA
(1.7)
Total Enterprise Value
2.6
TEV/EBITDA
NM
EBIT
(1.7)
Cash & ST Invst.
1.0
P/Diluted EPS Before Extra
NM
Net Income
(1.8)
Total Debt
0.8
Price/Tang BV
NM
Total Assets
1.2
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Matheson, J. Roderick
Executive Chairman & CEO
Williams, Mark 
President, Chief Science Officer & Director
Nijjar, Harpreet 
Chief Financial Officer
Groot, Jacqueline 
Corporate Secretary

Key Board Members
Name
Title
Matheson, J. Roderick
Executive Chairman & CEO
Williams, Mark 
President, Chief Science Officer & Director
Johnson, Neil A.
Lead Independent Director
Smallbone, S. Randall
Independent Director
Blum, David 
Member of Scientific Advisory Board
Cronstein, Bruce N.
Member of Scientific Advisory Board
Pedram, Babak 
Independent Director
Schweizer, Frank 
Member of Scientific Advisory Board
Young, Jared 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
505 8th Avenue S.W. Suit 420 | Calgary, AB | T2P 1G2 | Canada

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.07
Market Cap (mm)
2.8
Open
 0.07
Shares Out. (mm)
39.8
Previous Close
 0.07
Float %
81.6%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.07/ 0.07
Diluted EPS Excl. Extra Items
(0.05)
52 wk High/Low
 0.17/ 0.01
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0060
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.16


 
Delayed Quote** | Last Updated on Oct-05-2023 12:30 PM (GMT-5)
TSXV:MRVL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Alphanco Venture Corp.
As of June 14, 2021, Alphanco Venture Corp. was acquired by Marvel Biosciences Corp., in a reverse merger transaction. Alphanco Venture Corp. does not have significant operations. It identifies and evaluates businesses or assets with a view to completing a qualifying transaction. The company was incorporated in 2018 and is headquartered in West Vancouver, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-15-2023
-
Private Placement
Target
Marvel Biosciences Corp. (TSXV:MRVL)


1.12
Jun-21-2022
Aug-09-2022
Private Placement
Target
Marvel Biosciences Corp. (TSXV:MRVL)


0.56
Nov-03-2020
Jul-08-2021
Private Placement
Target
Marvel Biosciences Corp. (TSXV:MRVL)


4.21
Nov-03-2020
Jun-14-2021
Merger/Acquisition
Buyer
Alphanco Venture Corp.
Marvel Biosciences Corp. (TSXV:MRVL)

2.90
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-22-2023
Product-Related Announcements
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Jul-16-2023
Company Conference Presentations
Marvel Biosciences Corp. Presents at Alzheimer’s Association International Conference 2023, Jul-16-2023 07:00 AM
Mar-09-2023
Product-Related Announcements
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204
Feb-28-2023
Annual General Meeting
Marvel Biosciences Corp., Annual General Meeting, Feb 28, 2023
Feb-15-2023
Private Placements
Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in funding

M&A Advisors
McLeod Law LLP


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
McLeod Law LLP
Private Placement Advisors
Canaccord Genuity Corp., Raymond James Ltd., Research Capital Corporation


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Renaissance Mercantile Corp., Asset Management Arm

5,169,000

12.99

0.3

Feb-24-2023


Williams M.B.A., Ph.D., Mark 

5,000,049

12.57

0.3

Jan-23-2023


Matheson, J. Roderick

1,003,049

2.52

0.1

Jul-31-2023


Groot, Jacqueline 

645,000

1.62

0.0

Sep-26-2022


Abingdon Capital Corporation

280,000

0.70

0.0

Jan-23-2023


Pedram, Babak 

170,000

0.43

0.0

Jan-23-2023


Johnson, Neil A.

125,000

0.31

0.0

Jan-23-2023


Nijjar C.M.A., C.P.A., Harpreet 

100,000

0.25

0.0

Sep-26-2022


Virtus Advisory Group Inc., Asset Management Arm

28,500

0.07

0.0

Jan-23-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Matheson, J. Roderick
1,003,049
200,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
MB-204 (Future), Synthetic Chemical Derivatives (Future)


Upcoming Events
Date/Time
Type
Nov-16-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-22-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
53 KB
Jul-10-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
106 KB
Jun-23-2023
Apr-30-2023
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
Interim Financial Statements
280 KB
Apr-20-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
148 KB
Mar-30-2023
Jan-31-2023
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
Interim Financial Statements
275 KB
Mar-21-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
104 KB
Mar-09-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
91 KB
Feb-24-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
Material Change Report
120 KB
Feb-24-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
Securities Acquisition Filings (Early Warning)
113 KB
Feb-24-2023
-
Marvel Biosciences Corp. (TSXV:MRVL)
SEDAR
News Releases
175 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Matheson, J. Roderick (Executive Chairman & CEO)
Jul-31-2023
Common Shares
100,000
8,355
Open Market Acquisition
11.07
Multiple
Matheson, J. Roderick (Executive Chairman & CEO)
Jul-26-2023
Common Shares
100,000
8,315
Open Market Acquisition
12.45
Multiple
Nijjar C.M.A., C.P.A., Harpreet  (Chief Financial Officer)
Jul-19-2022
Common Shares
100,000
10,652
Private Acquisition
New
Multiple
Abingdon Capital Corporation
Jul-18-2022
Common Shares
250,000
26,573
Private Acquisition
833.33
Multiple
Fehr, Jeremy David (Former Independent Director)
Jul-18-2022
Common Shares
100,000
10,629
Private Acquisition
16.67
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Matheson, J. Roderick
Executive Chairman & CEO
403 770 2469
-

Williams, Mark 
President, Chief Science Officer & Director
403-770-2469
-

Johnson, Neil A.
Lead Independent Director
-
-

Smallbone, S. Randall
Independent Director
-
-

Blum, David 
Member of Scientific Advisory Board
-
-

Cronstein, Bruce N.
Member of Scientific Advisory Board
-
-

Pedram, Babak 
Independent Director
(416) 995-8651
-
bpedram@virtusadvisory.com
Schweizer, Frank 
Member of Scientific Advisory Board
-
-

Young, Jared 
Member of Scientific Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Matheson, J. Roderick
Executive Chairman & CEO
403 770 2469
-

Williams, Mark 
President, Chief Science Officer & Director
403-770-2469
-

Nijjar, Harpreet 
Chief Financial Officer
-
-

Groot, Jacqueline 
Corporate Secretary
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
